arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GRAIL, Inc.

GRAL
$108.46 ▲ +0.46 (+0.43%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
15 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

GRAIL, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7B
Dividend Yield
Revenue Growth 25.7%
Op. Margin -388.9%
ROIC -4.5%
FCF / Share $-1.88
Trailing P/E
Price / Book 1.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.69M
↑ +25.7%
Net Income Profit after all expenses
$-93.19M
↑ +12.3%
Operating Margin Operating profit as % of sales
-388.9%
↓ -16.8% 0th
FCF / Share Free cash flow per share
$-1.88
↑ +12.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
30
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 15 quarters